Literature DB >> 11772417

Lipoprotein changes with statins.

Evan A Stein1, Donald M Black.   

Abstract

The effects of statins and other lipid drugs are assessed by their ability to affect specific lipid fractions. Although there has been a great deal written abut the statins, most recent papers have focused on the comparative effects of the statins on triglycerides and high-density lipoprotein cholesterol, or have been concerned with the nonlipid effects of these drugs. In addition, some recent papers have focused on new parameters that may mediate cardiovascular risk, such as high-sensitivity C-reactive protein.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11772417     DOI： 10.1007/s11883-002-0057-8

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


  25 in total

Review 1.  Statin trials in progress: unanswered questions.

Authors:  M H Davidson
Journal:  Curr Atheroscler Rep       Date:  2001-01       Impact factor: 5.113

2.  Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors.

Authors:  W C Cromwell; P E Ziajka
Journal:  Am J Cardiol       Date:  2000-11-15       Impact factor: 2.778

3.  Comparison of lovastatin and gemfibrozil in normolipidemic patients with hypoalphalipoproteinemia.

Authors:  G L Vega; S M Grundy
Journal:  JAMA       Date:  1989-12-08       Impact factor: 56.272

4.  Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I.

Authors:  E Stein; R Kreisberg; V Miller; G Mantell; L Washington; D R Shapiro
Journal:  Arch Intern Med       Date:  1990-02

5.  Low-density lipoprotein size, pravastatin treatment, and coronary events.

Authors:  H Campos; L A Moye; S P Glasser; M J Stampfer; F M Sacks
Journal:  JAMA       Date:  2001-09-26       Impact factor: 56.272

6.  Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

Authors:  P Jones; S Kafonek; I Laurora; D Hunninghake
Journal:  Am J Cardiol       Date:  1998-03-01       Impact factor: 2.778

7.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.

Authors:  T A Pearson; I Laurora; H Chu; S Kafonek
Journal:  Arch Intern Med       Date:  2000-02-28

8.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

9.  Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.

Authors:  R G Bakker-Arkema; M H Davidson; R J Goldstein; J Davignon; J L Isaacsohn; S R Weiss; L M Keilson; W V Brown; V T Miller; L J Shurzinske; D M Black
Journal:  JAMA       Date:  1996-01-10       Impact factor: 56.272

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245
View more
  3 in total

1.  Atorvastatin decreases stearoyl-CoA desaturase gene expression in THP-1 macrophages incubated with oxidized LDL.

Authors:  Paula Martín-Fuentes; Angel Luis García-Otín; Luisa Calvo; Diego Gómez-Coronado; Fernando Civeira; Ana Cenarro
Journal:  Lipids       Date:  2008-11-04       Impact factor: 1.880

2.  Twelve-month treatment with Liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients.

Authors:  G T Russo; A M Labate; A Giandalia; E L Romeo; P Villari; A Alibrandi; G Perdichizzi; D Cucinotta
Journal:  J Endocrinol Invest       Date:  2014-08-31       Impact factor: 4.256

3.  Elevated atherosclerosis-related gene expression, monocyte activation and microparticle-release are related to increased lipoprotein-associated oxidative stress in familial hypercholesterolemia.

Authors:  Morten Hjuler Nielsen; Helle Irvine; Simon Vedel; Bent Raungaard; Henning Beck-Nielsen; Aase Handberg
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.